Transplacental passage of vancomycin during the second trimester of pregnancy.
Pharmacokinetics and drug monitoring of vancomycin were studied at mid-pregnancy in a patient with chorioamnionitis due to Streptococcus agalactiae. The terminal half-life remained in the normal range (4-6 hours) because of an equivalent increase in both volume of distribution and total plasma clearance. Transplacental passage of the drug was observed. Monitoring is mandatory for prolonged vancomycin therapy, and the results should be available within 24 hours. The therapeutic regimen of 15-20 mg/kg every 12 hours was sufficient for this patient's chorioamnionitis. Serum drug levels and renal function should be measured before increasing the vancomycin dosage.
Department of Gynecology and Obstetrics, Hôpital Antoine Beclere, Clamart, France.
P
P
Bourget
H
H
Fernandez
C
C
Delouis
F
F
Ribou
D000328:Adult; D000653:Amniotic Fluid / Q000737:chemistry; D002821:Chorioamnionitis / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D016903:Drug Monitoring; D005260:Female; D005312:Fetal Blood / Q000737:chemistry; D006801:Humans; D008431:Maternal-Fetal Exchange / Q000187:drug effects*; D011247:Pregnancy; D013290:Streptococcal Infections / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D013292:Streptococcus agalactiae; D014031:Tobramycin / Q000627:therapeutic use; D014640:Vancomycin / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use
D014640:Vancomycin; D014031:Tobramycin